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Abstract
Aims Over the last decade, major developments in medicine have led to signiﬁcant changes in the clinical management of
heart failure patients. This study was designed to evaluate the recent trends in clinical characteristics, management, and
short-term and long-term prognosis of patients with acute decompensated heart failure (ADHF) in Japan.
Methods and results The Kyoto Congestive Heart Failure study is a prospective, observational, multicentre cohort study,
enrolling consecutive ADHF patients from 19 participating hospitals in Japan from November 2014 to March 2016. A total
of 4000 patients will be enrolled into the study and patients’ anthropometric, socio-economic, and clinical data from hospital
admission to discharge will be collected. In addition, in a pre-determined subgroup of patients (n=1500), a longitudinal
follow-up for 2 years is scheduled.
Conclusions The Kyoto Congestive Heart Failure study will provide valuable information regarding patients with ADHF in the
real-world clinical practice of Japan and will be indispensable for future clinical and policy decision-making with respect to
heart failure.
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Introduction
Heart failure constitutes a major public health burden world-
wide.1 The number of annual hospitalizations for acute
decompensated heart failure (ADHF) continues to rise, and
the quality of life for these patients declines along with repeat
hospitalizations. In addition, mortality rates among patients
hospitalized with ADHF remain high.1 In Japan, the proportion
of people over 65 years reached 25% of the population in 2013
and will increase steadily until 2035, at which point the
Japanese population will start to decline. The number of
Japanese patients with heart failure was 979 000 in 2005
and is predicted to increase gradually as the population ages,
reaching 1.3 million by 2030. 2 Moreover, the westernization
of lifestyle and nutrition transition has facilitated the develop-
ment of coronary artery disease and a higher proportion of
ischaemic heart disease among heart failure patients.3,4
Consequently, Japanese patients with heart failure have
several unique clinical characteristics that might affect their
prognosis including a high prevalence of preserved ejection
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fraction (HFpEF), multiple comorbidities, and lack of
established treatment in elderly patients,5–7 and a longer
length of hospital stay.4 Furthermore, there is a higher
prevalence of angiotensin II receptor blockers use compared
with angiotensin-converting enzyme inhibitors use,4 and
common use of tolvaptan, a vasopressin V2 receptor antago-
nist, which is newly approved for heart failure only in
Japan.4,8,9
Although several observational studies of Japanese
patients with heart failure have been conducted during the
last two decades, these studies excluded patients who could
not agree in writing to the study consent form, which resulted
in non-consecutive patient enrolment and a sample that is not
truly representative of the current real-world clinical practice
of Japan.4,10,11 In addition, information regarding physical
ﬁndings and the socio-economic background of patients with
ADHF were limited in these previous studies. Therefore, the
Kyoto Congestive Heart Failure (KCHF) study was designed
to capture recent trends in clinical characteristics, socio-
economic factors, management, and prognosis of patients
with ADHF in the real-world clinical practice of Japan using a
prospective, observational, multicentre cohort design.
Study design
The participating study centres include 19 tertiary hospitals in
Tokai, Kinki, Chugoku, and Kyushu districts in Japan (Figure 1).
The KCHF study is a prospective observational registry of
patients hospitalized with ADHF. The KCHF study employs
consecutive enrolment and captures comprehensive data on
clinical and socio-economic characteristics, management
and outcomes, including in-hospital data assessment. In
addition, a longitudinal follow-up of 2 years is scheduled for
a pre-determined subgroup of patients.
Registry for consecutive patients with ADHF
All patients admitted to the participating centres with ADHF
as deﬁned by the modiﬁed Framingham criteria who undergo
heart failure-speciﬁc treatment involving intravenous drugs
within 24 h after hospital admittance are eligible for the
registry (Figure 2). Heart failure treatment will be at the dis-
cretion of the treating physician, according to the local prac-
tice. Patient enrolment started on October 2014 and ﬁnished
on March 2016 at each participating hospital. The estimated
number of patients that will be enrolled in the KCHF study
is 4000.
Longitudinal cohort study in a pre-determined
subgroup of patients
The KCHF longitudinal prospective cohort study involves a
follow-up period for 2 years from admission. Not all subjects
eligible for the KCHF registry will participate in the longitudi-
nal study (Figure 2). Exclusion criteria included: no consent
given for the longitudinal study, age <20 years, fever
Figure 1 Participating study centres include 19 hospitals in Tokai, Kinki, Chugoku, and Kyushu districts in Japan.
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(temperature >37.5°C) or diagnosed with infectious diseases
at admission, acute coronary syndrome, end-stage renal fail-
ure (serum creatinine, s-Cr >3.0 mg/dL or on haemodialysis),
severe comorbidity (i.e. end-stage cancer, end-stage liver
cirrhosis, or severe respiratory disease), or considered impos-
sible to follow-up (i.e. patients with dementia or cognitive
impairment, and patients living abroad). The estimated
number of the subgroup of patients that will be enrolled in
the longitudinal prospective cohort study is 1500.
Ethical issues and patient registration
The KCHF study was approved by the ethical committee at
Kyoto University Hospital (local identiﬁer: E2311) and at all
of the participating study hospitals. All studies will be
conducted in concordance with the principles outlined in the
Declaration of Helsinki. Written informed consent was ob-
tained from patients enrolled in the longitudinal prospective
cohort study. This study was registered with Clinicaltrials.gov
(Clinicaltrials.gov identiﬁer: NCT02334891).
Data collection in the registry for consecutive
patients with ADHF
Data collection will be conducted by the attending physicians
or the research assistants under the supervision of the clini-
cians responsible for this study at each participating hospital.
Data will be recorded with original recording paper or digital
ﬁles using Filemaker Pro 12 or 13 (Filemaker, Inc., Santa Clara,
CA, USA) at each participating hospital and then sent to the
data centre.
The proposed time frame for data collection during hospi-
talization and post-discharge is shown in Table 1. Physician-
investigators will enrol patients during the index admission
and collect data on patient demographics, past medical
history, socio-economic status (i.e. working status, long-term
care insurance status, place of residence and distance from
the hospitals, and the person(s) who live with the patient).
These factors are considered to affect the disease course of
heart failure. Laboratory, echocardiography, and electrocar-
diogram data, which were limited in previous studies, will
also be collected. Data regarding drugs used for the acute
management of heart failure as well as the medications taken
at admission and discharge will be collected. The signs and
symptoms of congestive heart failure have been reported to
be associated with the risk of exacerbation of heart failure.
Therefore, symptoms and physical ﬁndings will be evaluated
including: paroxysmal nocturnal dyspnoea, orthopnoea, dys-
pnoea on exertion, rales, ankle oedema, neck-vein distention,
pleural effusion, pulmonary oedema, appetite loss, lack of
sleep, general malaise, and thirst. Physical ﬁndings will be
assessed by attending physicians using a four-level symptom-
atic grading (0, None; 1, Seldom/Mild; 2, Frequent/Moderate;
3, Continuous/Severe) at four time points: at hospital arrival,
on admission, 24 h after hospital arrival, and at discharge. In
addition, ambulatory status (categorized as ambulatory,
wheelchair [outdoor only], wheelchair [outdoor and indoor],
or bedridden) will be evaluated at admission and at
discharge. The type of clinical scenario (CS; 1,2,3,4,5)12 on
admission, Nohria classiﬁcation (warm & dry, warm & wet,
Figure 2 Study design.
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cold & dry, or cold & wet)13, New York Heart Association
functional classiﬁcation (NYHA; I, II, III, VI)14 on admission
and at discharge will be evaluated. The rate of dyspnoea
relief at discharge will be evaluated by both patients and
the attending physician using a seven-level Likert-scale.
Details are shown in Table S2.
Clinical events such as in-hospital death (all-cause death,
cardiac death, heart failure death, sudden death, and non-
cardiac death), arrhythmic events (malignant ventricular
tachyarrhythmia, supraventricular tachyarrhythmia, appropri-
ate or inappropriate implantable cardioverter deﬁbrillator
shock, and symptomatic bradyarrhythmia), stroke (cerebral
infarction and haemorrhage), moderate to severe bleeding
events (global use of strategies to open occluded coronary
arteries bleeding deﬁnition; moderate to severe),15 adverse
drug events (ADEs), acute coronary events, and infectious dis-
eases during hospitalization will be evaluated. Cardiovascular
interventions (surgical and catheter procedures) and device
implantation during the index hospitalization will be regarded
as clinical events. In addition, worsening heart failure (WHF)
during hospitalization (deﬁned as additional intravenous drug
administration for heart failure treatment, haemodialysis, or
mechanical circulatory or respiratory support) and worsening
renal function (WRF; deﬁned as a rise in Cr ≥0.3 mg/dl
compared with the Cr level at admission), will be regarded
as clinical events.
Data collection in the longitudinal cohort study
In the pre-speciﬁed subgroup of patients enrolled in the
longitudinal cohort study, clinical data at 6, 12, and 24 months
after enrolment will be collected (Table 1). Data on clinical
events will be collected including all-cause death and a
composite endpoint of all-cause death and hospitalization
for heart failure exacerbation. Secondary endpoints include
cardiac death, non-cardiac death, sudden death, heart
failure death, hospitalization for heart failure exacerbation,
hospitalization for any reason, arrhythmia, stroke, cardiac
operation, moderate to severe bleeding events, ADEs,
symptoms of heart failure, changes in biomarkers, WRF, and
changes in echocardiographic parameters. Follow-up data
collection will be conducted through a review of medical
records, or by contacting the referring physicians or patients.
Quality assurance
To ensure the quality of the data, a study management
committee will meet every 2 months. For each meeting,
three or four participating hospitals will be randomly chosen
to be evaluated regarding the progress of data collection and
quality of the data by the chief of the study management
committee. The status of data collection and quality will be
assessed at the study management committee meeting.
Statistical analysis plan
(1) Registry for consecutive patients with ADHF
The primary analyses of the registry for consecutive
patients with ADHF aim to evaluate the quality of care in
the real-world clinical practice according to the current
clinical guidelines for heart failure. The proportion of patients
receiving optimal therapy at hospital discharge will be
analysed as one of the quality indicators for evidence-based
medicine. Variations in practice patterns and clinical
outcomes among the patients, participating hospitals, and
regions will be analysed. The outcomes included in the
primary analyses are the clinical characteristics, proportion
of elderly patients, comorbidities, medications taken pre-
admission, aetiology of heart failure, direct causes of ADHF,
pre-hospital activities, socio-economic factors, acute manage-
ment, clinical course during index hospitalization, and
differences in treatment decisions among the hospitals.
Short-term mortality and the prevalence of WHF during the
index hospitalization will also be analysed.
The secondary analyses include the examination of relation-
ships between clinical characteristics and in-hospital mortality
and pre-speciﬁed in-hospital adverse events. Patient age and
various causes of ADHF such as pneumonia and poor
Table 1 Data collection schedule for the Kyoto Congestive Heart Failure study
Registry Longitudinal follow-up study (month)
Hospitalization Hospital discharge 6 12 24
Patient background ○
Physical ﬁndings ○ ○ ○
Electrocardiogram ○ ○
Echocardiography ○ ○
Laboratory data/ Biomarker ○ ○ ○
Medication ○ ○ ○
Treatment ○ ○ ○
Event
KCHF, Kyoto Congestive Heart Failure
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adherence are expected to inﬂuence the prognosis and length
of hospital stay. Blood pressure, heart rate, body tempera-
tures, and physical ﬁndings at hospital arrival and on admis-
sion are expected to impact improvement in clinical status;
therefore, we will also analyse the relationship between these
factors and improvement in physical signs and symptoms.
Analysis of laboratory data at hospital arrival or on admission
and at discharge (including the status of congestion, myocar-
dial damage, WRF, inﬂammatory responses, and nutritional
status), is expected to elucidate the clinical characteristics of
patients with ADHF that link closely to the prognosis and clin-
ical events. The analysis of the data regarding the medication
administered intravenously or orally and the timing of newly
administered drugs is expected to elucidate the response to
therapy and the prevalence of WHF. The impact of the
intervention on the short-term prognosis and underlying
ischaemic heart disease during the hospitalization and
invasive monitoring will also be analysed.
Changes during hospitalization (including WRF, changes in
biomarkers, changes in symptoms and signs of heart failure,
and the changes in the patient’s activity) will be included in
focused analyses. Cross-sectional analyses of electrocardio-
graphic parameters, laboratory ﬁndings, and the ﬁndings of
echocardiography will also be performed. The mode of
discharge (discharge to the patient’s home, discharge to
another hospital for rehabilitation, or discharge to some-
where other than the patient’s home such as a care home)
will be analysed along with socio-economic and geographic
factors. The association between the prevalence of atrial
ﬁbrillation and cerebral infarction will be analysed along with
the data regarding administered novel anticoagulants and
haemodynamic changes. For the short-term outcomes
presented as binominal variables (i.e. in-hospital death),
univariate and multivariate logistic regression will be applied
to determine the factors that affect the outcome.
(2) Longitudinal prospective cohort study in a pre-determined
subgroup of patients
The primary analyses of the longitudinal cohort will
include the analysis of factors related to all-cause death, as
well as a composite endpoint of all-cause death and
hospitalization for the exacerbation of heart failure after
hospital discharge. The pre-designed secondary endpoints
will also be included in the analyses. The in-hospital factors
linking to the remote clinical events are the points in which
many clinicians are interested. Thus, the associations
between follow-up endpoints and the status at presentation,
WRF, exacerbation of heart failure, poly-pharmacy, the status
at discharge, non-pharmacological treatments, invasive
monitoring, and the use of inotropic agents and remote
events will be examined. A multivariate Cox proportional
hazard model will be applied to evaluate the factors
associated with long-term outcomes.
In addition, data regarding echocardiogram ﬁndings, symp-
toms and signs, and laboratory ﬁndings of patients with ADHF
in the chronic phase (6 months after hospital discharge) will
be analysed. Speciﬁcally, factors associated with changes in
the left ventricular dimension and ejection fraction in the
echocardiography, changes in brain natriuretic peptides and
troponins, changes in the sinus rhythm and atrial arrhythmias
or other arrhythmias, clinical characteristics, and medications
at hospital discharge will be analysed. When the data is
continuous, a linear regression model will be applied to
determine the association between the changes of these
two variables. In addition, multivariate logistic regression
analysis will be applied to evaluate the factors that affect
the binominal variables.
Furthermore, the titration and withdrawal of medications
at discharge and the continuation of drugs and add-on treat-
ments will be evaluated during the follow-up period. The
echocardiography data are expected to clarify the remodel-
ling and reverse remodelling of the left ventricle and will help
elucidate the overall clinical course of ADHF with various
aetiology and multiple comorbidities. In addition, the use of
anti-diabetic drugs will be evaluated, and the association
between the clinical course and the laboratory data will be
analysed. The impact of infectious diseases, thirst provoked
by decongestion, and appetite or malnutrition status on
clinical events will be assessed.
Missing data
When analysing data, we will report losses to observation
and to follow-up. If participants are excluded from analyses
because of missing or incomplete data, we will provide a sup-
plementary table that compares the observed characteristics
between participants with complete and incomplete data,
and we will include an assessment of data, whether missing
at random or not at random. Multiple imputation methods
will be used to impute missing data, if appropriate.
Discussion
The KCHF study is a prospective, observational, multicentre
cohort study designed to capture the recent trends in clinical
characteristics, socio-economic factors, management, and
prognosis of patients with ADHF in the real-world clinical
practice of Japan. The KCHF registry includes all patients
admitted to the participating centres with ADHF, avoiding
selection bias to elucidate a more complete picture of the
clinical characteristics, medications, and outcomes of patients
with ADHF.
The post-discharge readmission rate among heart failure
patients has been reported to be approximately 30% within
60 to 90 days, readmission ensures a signiﬁcant ﬁnancial
Kyoto Congestive Heart Failure (KCHF) study 5
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burden to the healthcare system.16,17 Despite these high
rates, very few previous studies on ADHF have collected
detailed data regarding post-discharge follow-up.18 The KCHF
study will collect post-discharge clinical data for 2 years in a
subgroup of patients. Detailed data regarding the manage-
ment of heart failure, signs and symptoms, electrocardio-
graphic ﬁndings, and laboratory ﬁndings will be collected at
6-months follow-up. Punnoose and colleagues19 have re-
ported that a signiﬁcant proportion of patients with HFpEF
have a history of reduced ejection fraction, and these
patients appeared to be clinically distinct from the residual
HF population.19 However, the details of serial changes in
ejection fraction of these patients have not been clearly
demonstrated.20 The KCHF study is designed to monitor
changes in ejection fraction and will provide further informa-
tion regarding this heart failure paradigm.
The longitudinal prospective cohort study does consist of a
non-consecutive group of patients from the KCHF registry.
We exclude patients with acute coronary syndrome, infec-
tious diseases, end-stage renal failure, and severe comorbid-
ity from the longitudinal cohort study, because the clinical
course of these patients depends largely on revascularization
therapy or other speciﬁc treatments unrelated to heart fail-
ure. Thus, including such patients would make the interpreta-
tion of the data complicated.
Over the last decade, all clinical trials involving new drugs,
apart from a few exceptions,21–24 have failed to demonstrate
improvement in the mortality of patients with ADHF and
chronic heart failure. Possible reasons may include
heterogeneity in the aetiology of heart failure and failure
to match the study therapy to the appropriate patient
subset. It is noteworthy that up to half of the patients with
heart failure have a normal or near-normal ejection
fraction,4 and that the mortality rate for HFpEF may be as
high as that for heart failure with reduced ejection fraction,
yet there is no effective treatment to improve clinical
outcomes in these patients.5–7
In addition, major developments in medicine have led to
signiﬁcant changes in the clinical management of heart
failure patients. Several new drugs have been approved by
the Japanese government: eplerenone was approved on
November 2007, and tolvaptan was approved for the ﬁrst
time in the world as a drug for heart failure treatment on
December 2010.9 Although a large-scale randomized con-
trolled trial failed to demonstrate the efﬁcacy of tolvaptan
on survival in patients with heart failure25 and it is not yet
recommended as a ﬁrst line therapy for ADHF in clinical
guidelines,26,27 it has grown in popularity as an effective drug
treatment for dyspnoea and oedema caused by heart failure
in Japan.8 Indeed, some of these pharmacological treatments
are unique to Japan. Other than tolvaptan, carperitide is also
available only in Japan, and the use of nicorandil and landiolol
for ADHF management is at present limited in Japan.28 In
addition, the estimated prevalence of HF in Japan is less than
1% at present, which is relatively low compared with Western
countries, and the ischaemic aetiology of ADHF is less
common in Japan than in Western countries.29 Although
there are several differences between Japan and other
countries in both characteristics and management of ADHF,
a comprehensive strategy for ADHF management ultimately
should not differ signiﬁcantly between Japan and other coun-
tries. Moreover, compared with other countries, Japan has
experienced a marked increase in the ageing population, 30
and the incidence of new onset heart failure has also rapidly
increased in recent years.2,29 As the result of the increase in
the ageing population, we are currently facing a worldwide
heart failure pandemic, and the risk is particularly great in
developed countries. The data that we plan to obtain in this
study from Japanese patients can provide valuable
information that can help to direct future clinical and policy
decision-making not only in Japan but also in other countries.
Moreover, ADEs related to polypharmacy, including the
new drugs described earlier as well as conventional medica-
tion for heart failure, will be prospectively evaluated in the
KCHF study. It has been reported that the epidemiology and
nature of ADEs and medication errors in Japan are similar
to other countries, although more frequent per admission.31
Evaluating the prevalence and severity of ADEs in heart
failure is highly important in order to provide optimal
medication, especially for elderly ADHF patients who were
excluded from previous studies.
In conclusion, the KCHF study promises to provide the
most comprehensive dataset regarding heart failure in
Japan to date. The analyses from this study will potentially
inﬂuence future clinical and policy decision-making, as well
as improve our understanding of the factors affecting the
disease course.
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